Key Highlights

  • Senti Biosciences shares are trading 13.31% higher at $0.21 after its merger closed on October 21, 2026.
  • Soluna Holdings is trading 10.48% higher at $0.72 with a planned 50 MW Texas AI data center venture in focus.
  • Transocean's all-stock Valaris combination is valued at about $5.8 billion, with a shareholder vote set for November 24, 2026.
  • Alaunos Therapeutics described a financing of about $350 million on October 13 alongside its Velaris Therapeutics acquisition.
  • T3 Defense agreed on October 27 to buy KeepZone AI for about $1 million, and the CERo Therapeutics Holdings go-shop ends around November 5 (calculated).

Which Merger and Deal Stories Are Behind the Stock Moves on October 28?

Six stocks tied to merger or acquisition news are in focus on Wednesday, October 28, 2026. Senti Biosciences (NASDAQ:SNTI) is trading 13.31% higher at $0.21 after its contingent value right merger closed, Soluna Holdings (NASDAQ:SLNH) is trading 10.48% higher at $0.72 on a planned Texas data center venture, and Transocean (NYSE:RIG) is trading 3.28% higher at $6.67 ahead of its all-stock combination with Valaris (NYSE:VAL). Alaunos Therapeutics (NASDAQ:TCRT) is trading 1.94% lower at $2.02 after closing the Velaris Therapeutics acquisition, while T3 Defense (NASDAQ:DFNS) at $3.85 and CERo Therapeutics Holdings (OTC:CERO), with a quote below one cent, are unchanged at 0.00%.

The sections below condense each story in order of the size of the move, then compare moves and deal sizes using only the figures stated. Figures marked calculated are derived from those numbers.

Senti Biosciences: What Do Holders Receive After the October 21 Merger Close?

Senti, a clinical-stage biotechnology company built around gene-circuit technology, completed its merger with ST NewCo on October 21, 2026. No cash is paid at closing. Each share instead carries one contingent value right that pays up to $60.0 million in total: $10.0 million when the FDA accepts a biologics license application for SENTI-202, $20.0 million on approval and $30.0 million once cumulative net sales exceed $200.0 million. Stockholders approved the deal on October 15 with 15,851,146 votes for and 4,325,620 against. Senior secured notes of $16.0 million are due to be exchanged today at $0.342 per share, which equals roughly 46.8 million shares (calculated) against 31.1 million outstanding at the record date. Cash was $6.5 million at June 30.

Soluna Holdings: What Is Behind the 10.48% Move After the Applied Digital Plan?

Soluna builds data centers beside wind, solar and hydroelectric plants, hosting Bitcoin mining and AI workloads. Shares are trading 10.48% higher at $0.72, an implied prior close of about $0.65 (calculated), after closing at $0.5197 on Monday, October 26. No company release is dated today. Recent news includes an October 21 plan with Applied Digital (NASDAQ:APLD) for a 50 MW facility near Silverton, Texas, in which Applied Digital is expected to hold 51% and Soluna 49%, and an October 26 statement that Soluna repaid its Generate Capital debt in full. Closing is targeted by December 31, 2026, subject to a county tax abatement, title policies, an operating agreement and definitive lease and power agreements.

Transocean: How Does 28% Short Interest Sit Beside the November 24 Valaris Vote?

Transocean operates 27 mobile offshore drilling units. Shares are trading 3.28% higher at $6.67, an implied prior close of about $6.46 (calculated), and no company release is dated today. The Valaris combination, announced in February 2026, is an all-stock deal valued at about $5.8 billion in which each Valaris share converts into 15.235 Transocean shares, leaving Transocean holders with about 53% of the combined company. Short interest was 312,674,405 shares for the October 15 settlement date, about 28.0% of the 1.12 billion shares outstanding, with 8.55 days to cover. The record date is November 9 and the extraordinary general meeting is set for Tuesday, November 24, 2026.

Alaunos Therapeutics: Why Is the Stock Slipping After the Velaris Deal and $350 Million Financing?

Alaunos is a clinical-stage biotechnology company that has shifted from T-cell receptor oncology toward obesity and cardiopulmonary programs. Shares are trading 1.94% lower at $2.02 with no announcement dated today, after a 25.00% fall on Friday, October 23 to $2.28. On October 13 it closed the acquisition of Velaris Therapeutics, a private developer of pulmonary arterial hypertension therapies, alongside a financing of about $350 million. Each Series C preferred share converts into 1,000 common shares after stockholder approval, implying about 358.59 million as-converted shares against 2.54 million outstanding. Short interest was 818,602 shares for the October 15 settlement date, about 32.2% of shares outstanding (calculated), and the reverse split ratio is not yet set.

T3 Defense: What Does the KeepZone AI Purchase Add to a Flat $3.85 Quote?

T3 Defense acquires and operates aerospace and defense businesses in the United States and Israel, including power generators for Iron Dome launchers and drone payload systems. Shares are unchanged at $3.85. On October 27, 2026 it agreed to acquire 100% of KeepZone AI from Nexera Technologies for about $1 million, adding a homeland security sales platform. Short interest was 489,971 shares for the October 15 settlement date, up from 276,275, or about 16% of the roughly 3.01 million shares outstanding (calculated). Trailing twelve-month revenue is $7.65 million.

CERo Therapeutics Holdings: Why Is an Unchanged Sub-Cent Quote Drawing Trading Interest?

CERo is an early-stage immunotherapy company in South San Francisco developing engineered T cell therapies for cancer. Shares are unchanged at 0.00%, with the price displayed as $0.00, meaning below one cent, and no company release dated today explains the activity. Under a stock purchase agreement signed on October 6, 2026, the company agreed to sell its operating subsidiary to SRX Global (NYSEAMERICAN:SRXH) for SRX stock valued at $1.0 million, cancellation of a senior secured note with $8,249,643.77 of principal plus accrued interest and fees, and assumption of about $1.562 million of liabilities. A 30-day go-shop ends around November 5 (calculated). Cash was $937,512 at June 30, with a working capital deficit of about $30.9 million and a going concern warning.

Merger and Deal Stories Compared: Which Moves and Deal Sizes Stand Apart?

Senti Biosciences' 13.31% gain is 2.83 percentage points above Soluna Holdings' 10.48% and 15.25 points above Alaunos Therapeutics' 1.94% decline, while Transocean's 3.28% gain is 5.22 points above that decline (all calculated). T3 Defense and CERo Therapeutics Holdings are both unchanged. On price, Transocean at $6.67 is $2.82 above T3 Defense at $3.85, which is $1.83 above Alaunos Therapeutics at $2.02 (calculated).

Deal sizes differ widely. The Transocean and Valaris combination, valued at about $5.8 billion, is about 5,800 times the roughly $1 million paid for KeepZone AI or offered in SRX stock for the CERo subsidiary (calculated). Alaunos Therapeutics' financing of about $350 million is about 69 times its market value of roughly $5.1 million, and Senti's note exchange equals about 1.5 times the shares outstanding at the record date (both calculated).

What to Watch Next: The Senti Note Exchange, the November 5 Go-Shop End and the November 24 Transocean Vote

Senti's note exchange is due today, October 28, with a resale registration statement due within 30 days of the October 21 closing. Valaris reports third-quarter results after the close on Monday, November 2, the CERo go-shop ends around November 5, and Transocean shareholders vote on November 24. Updated short-interest data for the October 30 settlement date are expected on November 10, covering Transocean, Alaunos Therapeutics and T3 Defense. Soluna's next earnings report is scheduled for November 16, and its Applied Digital transaction targets closing by December 31, 2026. Alaunos Therapeutics has not announced a date for its stockholder meeting, and T3 Defense has yet to detail the KeepZone AI closing.